Nihon Nohyaku Co., Ltd.
https://www.nichino.co.jp
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nihon Nohyaku Co., Ltd.
Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.
Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.
Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout
Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.
Generics Firms Can't Halt Maryland's 'Price Gouging' Law
Judge rejects Association for Accessible Medicines' bid for preliminary injunction, but industry can still pursue claims the statute's language is unconstitutionally vague; law goes into effect Oct. 1.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Other Names / Subsidiaries
-
- ADEKA Corporation
- Nichino Ryokka Co., Ltd.
- Nichino Service Co., Ltd.
- Nihon Ecotech Co., Ltd.
- AgriMart Corporation
- Nichino America, Inc.
- Nichino Europe Co., Ltd.
- Nichino Shanghai Co., Ltd.
- Nichino do Brasil Agroquimicos Ltda.
- Taiwan Nihon Nohyaku Co., Ltd.
- Nichino India Pvt. Ltd.
- Sipcam Nichino Brasil S.A.
- Nichino Vietnam Co., Ltd.
- Nihon Nohyaku Andica S.A.S.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice